美罗培南与磷霉素联合方案对多重耐药及产碳青霉烯酶肺炎克雷伯菌的体外时间杀菌与中空纤维感染模型药代动力学/药效学分析
该研究采用体外时间杀菌试验、药代动力学/药效学交互建模及中空纤维感染模型,评估美罗培南与磷霉素对四株产KPC-2或KPC-3的耐碳青霉烯肺炎克雷伯菌的联合效应。结果显示联合方案具有高杀菌效果并抑制再生长,美罗培南作为主药增强磷霉素效力,中空纤维模型证实持续抑制。作者认为联合方案在临床可达浓度下具有相加或协同潜力,但需进一步体内研究。
要点
- 美罗培南联合磷霉素对产KPC-2或KPC-3的耐碳青霉烯肺炎克雷伯菌在体外时间杀菌试验中显示高杀菌效果并抑制再生长。
- 药代动力学/药效学模型显示协同作用主要由美罗培南驱动,增强磷霉素的效力。
- 中空纤维感染模型证实联合方案持续抑制细菌生长,但作者指出需进一步体内研究以转化为临床实践。
核心结论
- 美罗培南与磷霉素在临床可达浓度下对产碳青霉烯酶的单耐药或双耐药肺炎克雷伯菌表现出相加或协同潜力。
- 联合方案可能作为多重耐药感染的一种策略,或可改善临床治疗结果。
- 需要进一步的体内研究以将这些发现转化为临床实践,强调PK/PD建模在合理使用抗生素中的重要性。
研究设计与样本
- 研究纳入四株从临床分离的多重耐药肺炎克雷伯菌,每株表达KPC-2或KPC-3。
- 采用静态时间杀菌试验,并考虑实测美罗培南降解。
- 随后进行药代动力学/药效学(PK/PD)交互建模,估计美罗培南降解速率常数并确定药效学交互中的主药-辅药关系。
- 使用动态中空纤维感染模型(HFIM)实验确认协同作用。
主要发现
- 静态时间杀菌试验显示,美罗培南与磷霉素联合相比单药治疗失败,表现出高杀菌效果并抑制再生长。
- 在细菌存在时美罗培南降解显著更高,归因于碳青霉烯酶活性。
- 药理学模型表明协同交互主要由美罗培南作为主药驱动,增强磷霉素的效力。
- HFIM实验证实体外协同作用,联合治疗显示持续细菌抑制。
临床怎么用
- 作者认为美罗培南与磷霉素联合方案可能作为多重耐药感染的一种策略,或可改善临床治疗结果。
- 作者指出需要进一步的体内研究以将这些发现转化为临床实践。
局限性
- 需要进一步的体内研究以将这些发现转化为临床实践。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: MDR Gram-negative bacteria, such as ESBL-producing and carbapenemase-producing Klebsiella pneumoniae, represent major global health threats. Treatment options are limited due to increasing resistance and slowed development of novel antimicrobials, making it necessary to apply effective combination therapies based on approved antibiotics. OBJECTIVES: To quantitatively evaluate the synergistic potential of meropenem and fosfomycin against carbapenem-resistant K. pneumoniae strains isolated from clinics. METHODS: We evaluated four MDR K. pneumoniae strains, each expressing KPC-2 or KPC-3, using static time-kill assays that accounted for measured meropenem degradation. This was followed by pharmacokinetic/pharmacodynamic (PK/PD) interaction modelling, which estimated meropenem degradation rate constants and identified perpetrator-victim relationships in PD interactions. Dynamic hollow-fibre infection model (HFIM) experiments were used to confirm synergy. RESULTS: Static time-kill assays demonstrated high killing effects and suppressed regrowth for the combination of meropenem and fosfomycin, compared with the failure of monotherapy. Meropenem degradation was significantly higher in the presence of bacteria, attributable to carbapenemase activity. Pharmacometric models indicated a synergistic interaction primarily driven by meropenem as the perpetrator, enhancing the potency of fosfomycin. HFIM experiments confirmed in vitro synergy, demonstrating continuous bacterial suppression of the combination therapy. CONCLUSIONS: Meropenem and fosfomycin exhibited additive or synergistic potential against carbapenemase-expressing single- or double-resistant K. pneumoniae at clinically achievable concentrations. This combination therapy may offer a strategy against MDR infections, possibly improving clinical treatment outcomes. Further in vivo research is needed to translate these findings into clinical practice, emphasizing the importance of PK/PD modelling in rationalizing antibiotic use.
引用
- Farooq A, Martens M, Kroemer N, et al. Pharmacokinetic/pharmacodynamic analysis of meropenem and fosfomycin combinations in in vitro time-kill and hollow-fibre infection models against multidrug-resistant and carbapenemase-producing Klebsiella pneumoniae. J Antimicrob Chemother. 2025. PMID: 39723630. doi:10.1093/jac/dkae459
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。